Surrozen (SRZN) Cash from Operations Growth (3y) (2023 - 2026)
Surrozen (SRZN) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Ops. Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
788,338.31 Bn |
788,338.28 Bn |
- |
- |
| 2 |
Belite Bio |
56,560.00 Bn |
56,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,329.30 Bn |
17,329.30 Bn |
- |
- |
| 4 |
Legend Biotech |
3,341.00 Bn |
3,340.71 Bn |
242.10 Mn |
37.40% |
| 5 |
Akari Therapeutics |
1,727.91 Bn |
1,727.91 Bn |
- |
20.11% |
| 6 |
Evaxion A |
1,536.68 Bn |
1,536.67 Bn |
- |
- |
| 7 |
Psyence Biomedical |
238.34 Bn |
238.33 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.42 Bn |
106.17 Bn |
2.59 Bn |
16.64% |
| 9 |
Abivax |
95.45 Bn |
95.45 Bn |
- |
- |
| 10 |
Surrozen |
239,016.67 |
-106.67 Mn |
- |
4.11% |
| Date | Value |
|---|
| Mar 31, 2026 |
4.11% |
| Dec 31, 2025 |
-231.79% |
| Sep 30, 2025 |
14.01% |
| Jun 30, 2025 |
18.78% |
| Mar 31, 2025 |
20.34% |
| Dec 31, 2024 |
32.08% |
| Sep 30, 2024 |
21.69% |
| Jun 30, 2024 |
23.99% |
| Mar 31, 2024 |
5.57% |
| Dec 31, 2023 |
-98.45% |
